P2RY12 and atrial fibrillation: Standard antithrombotic therapy in the year after an ACS event currently comprises dual antiplatelet therapy (ASA plus a P2Y12 inhibitor), so patients with AF who have experienced an ACS event have indications for both anticoagulant and antiplatelet therapy [51–54].